Fairvalue-Calculator Fairvalue-Calculator
EN DE

Kane Biotech Inc (KNBIF) Fair Value & Analysis

Healthcare · US · Market cap $5.1M

Price$0.0250
Fair Value$0.0100
Upside-60.0%
Quality95/100
Evidence: Low

Fair value as of: Jun 23, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Kane Biotech Inc (KNBIF) currently trades at $0.0250, while our model-based Fair Value estimate is $0.0100 — implying the stock looks roughly 60.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, a biofilm destabilizing formula with continuous activity; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG) for treating wounds and otic infections. Its wound care product portfolio includes antimicrobial wound gel, antimicrobial wound gel spray, and antimicrobial wound rinse under revyve name, as well as antimicrobial surgical hydrogel under coactiv+ name. In addition, the company offers scalp detoxifier product line under the Omni Bioceuticals brand. Further, it engages in developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; revyve Antimicrobial Wound Rinse for use in acute and chronic wounds…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Kane Biotech Inc (KNBIF) undervalued?
As of Jun 23, 2026, our model estimates a fair value of $0.0100 versus a price of $0.0250 — about −60% (overvalued). Model-based estimate, not financial advice.
What is the fair value of KNBIF?
Our 21-model fair value for Kane Biotech Inc is $0.0100 (as of Jun 23, 2026), built from audited fundamentals. The current price is $0.0250.
What is the quality score of KNBIF?
Kane Biotech Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.